Publications:

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.

Cell Research

Jiang, Yi-Zhou YZ; Liu, Yin Y; Xiao, Yi Y; Hu, Xin X; Jiang, Lin L; Zuo, Wen-Jia WJ; Ma, Ding D; Ding, Jiahan J; Zhu, Xiaoyu X; Zou, Jianjun J; Verschraegen, Claire C; Stover, Daniel G DG; Kaklamani, Virginia V; Wang, Zhong-Hua ZH; Shao, Zhi-Ming ZM

Publication Date: 2021-02

Variant appearance in text: RET: 754G>A; E252K

PubMed Link: 32719455

Variant Present in the following documents:

• 41422_2020_375_MOESM12_ESM.xlsx, sheet 1

View BVdb publication page

Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.

Cancer Biology & Therapy

Kim, Eun Young EY; Cho, Eun Na EN; Park, Heae Surng HS; Hong, Ji Young JY; Lim, Seri S; Youn, Jong Pil JP; Hwang, Seung Yong SY; Chang, Yoon Soo YS

Publication Date: 2016

Variant appearance in text: RET: 754G>A

PubMed Link: 26785607

Variant Present in the following documents:

• Main text

View BVdb publication page

Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.

Bmc Cancer

Kim, Eun Young EY; Cho, Eun Na EN; Park, Heae Surng HS; Kim, Arum A; Hong, Ji Young JY; Lim, Seri S; Youn, Jong Pil JP; Hwang, Seung Yong SY; Chang, Yoon Soo YS

Publication Date: 2016-01-18

Variant appearance in text: RET: 754G>A

PubMed Link: 26782967

Variant Present in the following documents:

• 12885_2016_2049_MOESM1_ESM.xlsx, sheet 1

View BVdb publication page